155 related articles for article (PubMed ID: 31982107)
1. Fluctuation analysis of postoperative secretory status in patients operated for acromegaly.
Graillon T; Castinetti F; Boucekine M; Cuny T; Morange I; Fuentes S; Figarella-Branger D; Albarel F; Brue T; Dufour H
Ann Endocrinol (Paris); 2020 Feb; 81(1):11-17. PubMed ID: 31982107
[TBL] [Abstract][Full Text] [Related]
2. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
3. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
4. [Outcome of surgical treatment for acromegaly performed by a single neurosurgeon and cumulative meta-analysis].
Boeving A; Borba LA; Rodrigues AM; Orichowski EB; Paz Filho GJ; Santos CM; Boguszewski CL
Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):884-92. PubMed ID: 17160212
[TBL] [Abstract][Full Text] [Related]
5. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
6. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
7. Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases.
He W; Yan L; Wang M; Li Q; He M; Ma Z; Ye Z; Zhang Q; Zhang Y; Qiao N; Lu Y; Ye H; Lu B; Shou X; Zhao Y; Li Y; Li S; Zhang Z; Shen M; Wang Y
Endocrine; 2019 Jan; 63(1):27-35. PubMed ID: 30238327
[TBL] [Abstract][Full Text] [Related]
8. Ectopic GH-secreting pituitary adenoma of the clivus: systematic literature review of a challenging tumour.
Riccio L; Donofrio CA; Tomacelli G; De Blasi R; Melatini A
Pituitary; 2020 Aug; 23(4):457-466. PubMed ID: 32504302
[TBL] [Abstract][Full Text] [Related]
9. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Freda PU; Nuruzzaman AT; Reyes CM; Sundeen RE; Post KD
J Clin Endocrinol Metab; 2004 Feb; 89(2):495-500. PubMed ID: 14764751
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.
Kinoshita Y; Tominaga A; Usui S; Arita K; Sakoguchi T; Sugiyama K; Kurisu K
Neurosurg Rev; 2016 Apr; 39(2):313-8; discussion 318-9. PubMed ID: 26785642
[TBL] [Abstract][Full Text] [Related]
11. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
12. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
13. Surgical and Pharmacological Outcomes in Acromegaly: Real-Life Data From the Mexican Acromegaly Registry.
Mercado M; Abreu C; Vergara-López A; González-Virla B; Espinosa-de-Los-Monteros AL; Sosa-Eroza E; Cadena-Obando D; Cuevas-Ramos D; Portocarrero-Ortiz LA; Pérez-Reyes SP; Mercado-Cherem A; Ibarra-Salce R; Talavera JO
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32944780
[TBL] [Abstract][Full Text] [Related]
14. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
[TBL] [Abstract][Full Text] [Related]
16. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature.
Minniti G; Jaffrain-Rea ML; Esposito V; Santoro A; Tamburrano G; Cantore G
Endocr Relat Cancer; 2003 Dec; 10(4):611-9. PubMed ID: 14713271
[TBL] [Abstract][Full Text] [Related]
17. Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.
Coopmans EC; Postma MR; Wolters TLC; van Meyel SWF; Netea-Maier R; van Beek AP; Neggers SJCMM
J Clin Endocrinol Metab; 2021 May; 106(6):1783-1792. PubMed ID: 33544833
[TBL] [Abstract][Full Text] [Related]
18. The common consensus criteria have high predictive values for long-term postoperative acromegaly remission.
Kristof RA; Grote A; Redel L; Neuloh G; Klingmüller D; Schramm J
Acta Neurochir (Wien); 2011 Jan; 153(1):19-25. PubMed ID: 20845050
[TBL] [Abstract][Full Text] [Related]
19. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
20. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
